Night-phase orexin receptor antagonism rescues AD by restoring sleep-dependent clearance

Target: HCRTR2 Composite Score: 0.758 Price: $0.71▼10.4% Citation Quality: 64% neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
🏆 ChallengeSolve: Night-phase orexin receptor antagonism rescues AD by restoring $126K bounty →
✓ All Quality Gates Passed
Evidence Strength Strong (64%)
8
Citations
1
Debates
8
Supporting
2
Opposing
Quality Report Card click to collapse
B+
Composite: 0.758
Top 8% of 1875 hypotheses
Unknown
B+ Mech. Plausibility 15% 0.77 Top 22%
B+ Evidence Strength 15% 0.73 Top 13%
C+ Novelty 12% 0.58 Top 72%
A Feasibility 12% 0.84 Top 22%
B+ Impact 12% 0.76 Top 41%
A Druggability 10% 0.86 Top 20%
B+ Safety Profile 8% 0.70 Top 22%
C+ Competition 6% 0.55 Top 65%
B Data Availability 5% 0.65 Top 45%
B Reproducibility 5% 0.62 Top 41%
Evidence
8 supporting | 2 opposing
Citation quality: 64%
Debates
1 session B+
Avg quality: 0.78
Convergence
0.68 B 30 related hypothesis share this target

From Analysis:

Orexin-A manipulation in AD cognition and circadian dysfunction

Does manipulating orexin-A directly rescue cognitive deficits and circadian dysfunction in Alzheimer's disease models?

→ View full analysis & debate transcript

Description

Timed OX1R/OX2R antagonism during the rest phase may consolidate sleep, improve glymphatic/interstitial clearance, and reduce amyloid or tau stress while avoiding daytime cognitive suppression. The therapeutic effect should depend on circadian timing.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
A["Night-phase OX1R/OX2R Antagonism"] -->|"Restores sleep architecture"| B["Sleep Consolidation"]
A -->|"Target: HCRTR2"| C["Orexin Signaling Suppression"]
C -->|"Disinhibition of NREM sleep"| B
B -->|"Enhances convective flow"| D["Glymphatic Clearance Activation"]
D -->|"Increases ISF drainage"| E["Interstitial A-beta Reduction"]
D -->|"Clears metabolite waste"| F["Tau Phosphorylation Decrease"]
E -->|"Reduces seeding events"| F
F -->|"Prevents neurofibrillary tangle formation"| G["Synaptic Protection"]
A -->|"Avoids daytime orexin blockade"| H["Preserved Daytime Cognition"]
G -->|"Maintains neuronal signaling"| I["Cognitive Function Rescue"]
H -->|"No executive suppression"| I
E -->|"Decreases amyloid plaque burden"| I
G -->|"Prevents progressive neurodegeneration"| J["AD Pathology Attenuation"]
I -->|"Clinical benefit"| K["Memory Improvement"]
K -->|"Therapeutic outcome"| L["Disease Modification"]

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for HCRTR2 from GTEx v10.

Hypothalamus0.8 Frontal Cortex BA90.4 Cortex0.3 Anterior cingulate cortex BA240.3 Nucleus accumbens basal ganglia0.2 Substantia nigra0.2 Amygdala0.2 Caudate basal ganglia0.1 Putamen basal ganglia0.1 Cerebellum0.0 Cerebellar Hemisphere0.0 Hippocampus0.0 Spinal cord cervical c-10.0median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.77 (15%) Evidence 0.73 (15%) Novelty 0.58 (12%) Feasibility 0.84 (12%) Impact 0.76 (12%) Druggability 0.86 (10%) Safety 0.70 (8%) Competition 0.55 (6%) Data Avail. 0.65 (5%) Reproducible 0.62 (5%) KG Connect 0.58 (8%) 0.758 composite
10 citations 8 with PMID 5 medium Validation: 64% 8 supporting / 2 opposing
For (8)
5
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
7
2
1
MECH 7CLIN 2GENE 1EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Interaction between Aβ and Tau in the Pathogenesis…SupportingMECHInt J Biol Sci MEDIUM2021-PMID:34239348-
Site-Specific Phospho-Tau Aggregation-Based Biomar…SupportingCLINACS Chem Neuros… MEDIUM2022-PMID:36350059-
Quantitative Assessment of Hippocampal Tau Patholo…SupportingMECHJ Mol Neurosci MEDIUM2020-PMID:32372343-
Roles of Microglia in AD Pathology.SupportingMECHCurr Alzheimer … MEDIUM2023-PMID:36740796-
TDP-43 pathology is associated with increased tau …SupportingMECHMol Neurodegene… MEDIUM2023-PMID:37777806-
No claimSupportingMECHOrexin-A and Ci…-2025-PMID:41335394-
No claimSupportingMECHGlymphatic fail…-2020---
Hypocretin/Orexin Receptor Pharmacology and Sleep …SupportingCLINFront Neurol Ne…-2021-PMID:34052813-
No claimOpposingMECH------
Combined effects of HCRTR1/2 gene variants and non…OpposingGENEPharmacol Rep-2025-PMID:40439868-
Legacy Card View — expandable citation cards

Supporting Evidence 8

No claim
Orexin-A and Circadian Disruption in Alzheimer's Disease · 2025 · PMID:41335394
No claim
Glymphatic failure as a final common pathway to dementia · 2020
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Front Neurol Neurosci · 2021 · PMID:34052813
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease. MEDIUM
Int J Biol Sci · 2021 · PMID:34239348
Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation. MEDIUM
ACS Chem Neurosci · 2022 · PMID:36350059
Quantitative Assessment of Hippocampal Tau Pathology in AD and PART. MEDIUM
J Mol Neurosci · 2020 · PMID:32372343
Roles of Microglia in AD Pathology. MEDIUM
Curr Alzheimer Res · 2023 · PMID:36740796
TDP-43 pathology is associated with increased tau burdens and seeding. MEDIUM
Mol Neurodegener · 2023 · PMID:37777806

Opposing Evidence 2

No claim
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake transition and hemodynamic st…
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake transition and hemodynamic stability during propofol, dexmedetomidine, and remifentanil anesthesia.
Pharmacol Rep · 2025 · PMID:40439868
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Orexin-A may be therapeutic only when the intervention restores circadian phase and sleep architecture. Nighttime OX1R/OX2R antagonism could improve glymphatic clearance, whereas daytime orexin tone may support attention and synaptic function.

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

The same arousal pathway can increase amyloid production by extending wakefulness. A rescue claim must show that benefits are not merely sedation, reduced activity, or nonspecific sleep extension.

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

The translational path is feasible because orexin receptor antagonists are clinically available. Trials would need actigraphy, polysomnography, plasma/CSF p-tau or Abeta markers, and next-day cognitive safety monitoring.

Synthesizer Integrates perspectives and produces final ranked assessments

Ranked synthesis: circadian-timed receptor antagonism is strongest, glymphatic-clearance rescue is the key mechanism to test, and daytime orexin support remains speculative but worth biomarker-led study.

Price History

0.680.720.77 0.81 0.64 2026-04-262026-04-272026-04-27 Market PriceScoreevidencedebate 7 events
7d Trend
Falling
7d Momentum
▼ 10.4%
Volatility
High
0.0821
Events (7d)
7

Clinical Trials (3) Relevance: 76%

0
Active
0
Completed
0
Total Enrolled
PHASE2
Highest Phase
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease PHASE4
RECRUITING · NCT05924425 · University Hospital, Montpellier
Alzheimer Disease Insomnia Disorder Sleep
Daridorexant 50 mg Placebo Polysomnography
Daridorexant for Alzheimer Disease Prevention PHASE2
RECRUITING · NCT07213349 · Douglas Mental Health University Institute
Alzheimer Disease (AD)
Daridorexant 50 mg Placebo
DORA and LP in Alzheimer's Disease Biomarkers PHASE2
RECRUITING · NCT06274528 · Washington University School of Medicine
Alzheimer Disease
Lemborexant 10 mg Lemborexant 20mg Placebo

📚 Cited Papers (8)

No extracted figures yet
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Front Neurol Neurosci (2021) · PMID:34052813
No extracted figures yet
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
International journal of biological sciences (2022) · PMID:34239348
No extracted figures yet
No extracted figures yet
No extracted figures yet
TDP-43 pathology is associated with increased tau burdens and seeding.
Molecular neurodegeneration (2023) · PMID:37777806
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.72
46.4th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
8

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.072
10% weight of efficiency score
Adjusted Composite
0.830

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for HCRTR2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HCRTR2 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

Orexin-Microglia Modulation Therapy
Score: 0.707 | neurodegeneration
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.907 | neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 | neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 | neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 HCRTR2 — PDB 7L1U Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Orexin-A manipulation in AD cognition and circadian dysfunction

neurodegeneration | 2026-04-26 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

Excess orexin-A worsens AD cognition through wake-driven amyloid produ
Score: 0.71 · HCRT
Daytime orexin tone preserves synaptic plasticity in prodromal AD
Score: 0.65 · HCRTR1
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.